SCHEMBL24371391

SCHEMBL24371391

COc1cc(C(C)C)c(C)cc1C(C)=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
TSHR P16473 3/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CA9 Q16790 1/20 0.42
KCNK3 O14649 1/20 0.41
KCNK9 Q9NPC2 1/20 0.41
GAA P10253 2/20 0.41
GFER P55789 1/20 0.41
SRC P12931 1/20 0.41
TGFBR1 P36897 1/20 0.41
CYP3A4 P08684 3/20 0.41
ALDH1A1 P00352 3/20 0.40
P2RX3 P56373 2/20 0.39
P2RX2 Q9UBL9 2/20 0.39
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17948554 0.82 CYP3A4 (0.47) HTTTSHRPOLBMAPTHPGD
SCHEMBL30482808 0.81 SRC (0.54) HTTTSHRMAPTHPGDHSD17B10
SCHEMBL17363694 0.81 SRC (0.54) HTTTSHRMAPTHPGDHSD17B10
SCHEMBL9417797 0.80 CYP3A4 (0.52) HTTTSHRHPGDHSD17B10CA9
SCHEMBL13978807 0.79 POLB (0.49) HTTTSHRPOLBMAPTHPGD
SCHEMBL2758296 0.77 GAA (0.57) TSHRPOLBMAPTHPGDHSD17B10
SCHEMBL20630769 0.77 HTT (0.68) HTTTSHRHPGDHSD17B10CA9
SCHEMBL2423890 0.77 HTT (0.63) HTTTSHRMAPTHPGDHSD17B10
SCHEMBL17755147 0.76 POLB (0.52) TSHRPOLBMAPTHPGDHSD17B10
SCHEMBL7685964 0.76 HTT (0.57) HTTTSHRHPGDHSD17B10CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
WO-2022083703-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR5 HTT 2780/4885TSHR 925/4885POLB 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.